Ann: Chimeric partnering with Cell Therapies Australia, page-3

CHIMERIC PARTNERING WITH CELL THERAPIES AUSTRALIA
Sydney, Australia, 09 August 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the
“Company”), an Australian leader in cell therapy, is pleased to announce a collaboration with Cell
Therapies Pty Ltd to explore the potential to manufacture Chimeric’s CAR T assets in Australia.
Cell Therapies Pty Ltd (“CTPL” or “Cell Therapies”) is an Australian based commercial contract
development and manufacturing company, specialising in cell therapy, gene therapy,
regenerative medicine, and cellular immunotherapy products. CTPL’s facilities are co-located
with the Peter MacCallum Cancer Centre in Melbourne’s Parkville Precinct and are Australia’s
only biomedical manufacturing facility where CAR T-cells and other “living” cancer therapies can
be made at a commercial scale.
Chimeric currently has four Phase 1/1b trials open across the United States and is exploring the
addition of new sites in Australia.
“This is great progress for Chimeric and aims to provide Australian patients with access to our
first in class CAR T clinical trials,” said Dr Rebecca McQualter, Chief Operating Officer of Chimeric
Therapeutics.
“We are very pleased to work with Chimeric to bring their innovative CAR T products to Australian
cancer patients in need,” said Dr Bev Menner, Chief Executive Office of Cell Therapies